Skye Bioscience Inc(SKYE) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 5 at 4:00 PM ET (Korea 11/6 06:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -10.18 | Insider Own | 32.76% | Shs Outstand | 4.4M | Perf Week | -20.61% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | -13.96% | Insider Trans | -43.48% | Shs Float | 3.0M | Perf Month | -36.97% |
| Enterprise Value | -0.01B | PEG | - | EPS next Q | -1.14 | Inst Own | 18.32% | Short Float | 4.71% | Perf Quarter | -74.97% |
| Income | -0.05B | P/S | - | EPS this Y | 47.52% | Inst Trans | 7.9% | Short Ratio | 1.55 | Perf Half Y | -85.53% |
| Sales | 0.00B | P/B | - | EPS next 5Y | 1.68% | ROA | -159.8% | Short Interest | 0.14M | Perf YTD | -82.66% |
| Book/sh | -0.11 | P/C | 0.46 | EPS past 3/5Y | 45.62% 28.34% | ROE | -233.87% | 52W High | -91.87% ($12.80) | Perf Year | -91.39% |
| Cash/sh | 2.27 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | -6.31% ($1.11) | Perf 3Y | -92.35% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -19.07% | Gross Margin | - | Volatility(W/M) | 11.47% 8.56% | Perf 5Y | -99.39% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.15 | Perf 10Y | -99.9% |
| Dividend Ex-Date | - | Quick Ratio | 0.95 | EPS Q/Q | 38.85% | Profit Margin | - | RSI (14) | 25.39 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.95 | Sales Q/Q | - | SMA20 | -29.01% ($1.46) | Beta | 3.15 | Target Price | $16 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/14 | SMA50 | -37.18% ($1.66) | Rel Volume | 0.39 | Prev Close | $1.14 |
| Employees | 12 | LT Debt/Eq | - | EPS/Sales Surpr. | -13.3% - | SMA200 | -77.99% ($4.73) | Avg Volume(3M) | 0.09M | Price | $1.04 |
| IPO | 2014/11/26 | Option/Short | No/Yes | Trades | 194 | Volume | 35,477 | Change | -8.77% |
Sky Bioscience () is a clinical-stage biotech headquartered in San Diego, California, USA, developing 'nimacimab,' an obesity-treatment antibody leveraging a peripherally selective CB1 receptor inhibition mechanism, as its core pipeline. The company aims to address the limitations of existing obesity therapies through combination strategies with GLP-1 class drugs (semaglutide and tirzepatide), positioning itself as a next-generation treatment approach for obesity and metabolic diseases.
Over the past 1 year, on the lower side
92% below its 1-year high.
Traded less than usual. That is 39% of its average volume.
SKYE has weak earning power
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +47.5% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.4%. The S&P 500 did +56% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 18.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #545 of 597 in the industry
Based on market cap of $5M.
CANF#543 Can-Fite Biopharma Ltd ADR $5M PER - 
NIKI#544 Niki BioSolutions Inc $5M PER - SKYE#545 Skye Bioscience Inc $5M PER - 
AZTR#546 Azitra Inc $4M PER - 
XBIO#547 Xenetic Biosciences Inc $4M PER - 
FAQ
What kind of company is SKYE?
SKYE belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of SKYE?
The market cap of SKYE is approximately $5M, ranking 5,622 within its sector.
What is the 52-week high and low for SKYE?
SKYE has recorded a 52-week high of $12.80 and a low of $1.11.
